Drug intelligence / Profile preview

Qinhuai Capsules

Development stage: Unknown
Lead developer: Jilin Tianheng Pharmaceutical
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

Qinhuai Capsules (秦槐胶囊) is a botanical drug candidate developed by Jilin Tianheng Pharmaceutical for the treatment of gout and hyperuricemia. It is currently undergoing Phase II clinical evaluation in China as a urate-lowering therapy. The drug is formulated as an oral capsule and is designed to manage serum uric acid levels in adults with hyperuricemia or gouty arthritis. Clinical studies, such as the randomized, double-blind, placebo-controlled trial CTR20243105, have focused on assessing the efficacy and safety of the capsules over a multi-week treatment period, including a placebo run-in phase.

Brand names: Qinhuai Capsules
Other names: 秦槐胶囊

Beyond the preview

Go deeper on Qinhuai Capsules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qinhuai Capsules.

Explore the full profile